Efficacy and safety of rivaroxaban in real-life patients with atrial fibrillation

References

• Rahman F, Kwan GF, Benjamin EJ. Global epidemiology of atrial fibrillation. Nat Rev Cardiol 2014;11:639-54
   PubMed Web of Science ®Google Scholar
• Zoni-Berisso M, Lercari F, Carazza T, Domenicucci S. Epidemiology of atrial fibrillation: European perspective. Clin Epidemiol 2014;6:213-20
   PubMed Web of Science ®Google Scholar
• Vora A, Narasimhan C. Stroke prevention in atrial fibrillation – current standard of care and significant unmet medical need. J Assoc Physicians India 2013;61:904-6
   PubMedGoogle Scholar
• Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke 1991;22:983-8
   PubMed Web of Science ®Google Scholar
• Masjuán J, Álvarez-Sabín J, Blanco M, et al. Current management of antithrombotic treatment in patients with non valvular atrial fibrillation and prior history of stroke or transient ischemic attack. Rev Neurol 2014;59:25-36
   PubMed Web of Science ®Google Scholar
• Barrios V, Calderon A, Escobar C, de la Figuera M. Patients with atrial fibrillation in a primary care setting: val-FAAP study. Rev Esp Cardiol 2012;65:47-53
   PubMed Web of Science ®Google Scholar
• Barrios V, Escobar C, Calderón A, et al. Use of antithrombotic therapy according to CHA2DS2-VASc score in patients with atrial fibrillation in primary care. Rev Esp Cardiol 2014;67:150-1
   PubMed Web of Science ®Google Scholar
• Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med 2007;146:857-67
   PubMed Web of Science ®Google Scholar
• Hylek EM, Go AS, Chang Y, et al. Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation. N Engl J Med 2003;349:1019-26
   PubMed Web of Science ®Google Scholar
• Gallego P, Roldán V, Lip GY. Novel oral anticoagulants in cardiovascular disease. J Cardiovasc Pharmacol Ther 2014;19:34-44
   PubMed Web of Science ®Google Scholar
• Martínez-Rubio A, Dan GA, Kaski JC. Rivaroxaban and stroke prevention in patients with atrial fibrillation: new evidence. Expert Rev Cardiovasc Ther 2014;12:933-47
   PubMedGoogle Scholar
• Morgan CL, McEwan P, Tukiendorf A, et al. Warfarin treatment in patients with atrial fibrillation: observing outcomes associated with varying levels of INR control. Thromb Res 2009;124:37-41
   PubMed Web of Science ®Google Scholar
• Nelson WW, Desai S, Damaraju CV, et al. International normalized ratio stabilization in newly initiated warfarin patients with nonvalvular atrial fibrillation. Curr Med Res Opin 2014;30:2437-42
   PubMed Web of Science ®Google Scholar
• Anguita Sanchez M, Cequier Fillat A, Bertomeu Martinez V. Bad control of anticoagulation with vitamin K antagonists in patients with non-valvular atrial fibrillation in Spain: current prevalence and associated factors. Rev Esp Cardiol 2014;67(Suppl 1):A5010-14
   Google Scholar
• Dlott JS, George RA, Huang X, et al. National assessment of warfarin anticoagulation therapy for stroke prevention in atrial fibrillation. Circulation 2014;129:1407-14
   PubMed Web of Science ®Google Scholar
• Caldeira D, Cruz I, Morgado G, et al. Evaluation of time in therapeutic range in anticoagulated patients: a single-center, retrospective, observational study. BMC Res Notes 2014;7:891
   PubMedGoogle Scholar
• Ruff CT, Giugliano RP, Braunwald E, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet 2014;383:955-62
   PubMed Web of Science ®Google Scholar
• Savelieva I, Camm AJ. Practical considerations for using novel oral anticoagulants in patients with atrial fibrillation. Clin Cardiol 2014;37:32-47
   PubMed Web of Science ®Google Scholar
• Barrios V, Escobar C. Rivaroxaban: a once-daily anticoagulant for the prevention of thromboembolic complications. Expert Rev Cardiovasc Ther 2013;11:129-41
   PubMedGoogle Scholar
• Steg PG, Lopez-Sendon J, Lopez de Sa E, et al. External validity of clinical trials in acute myocardial infarction. Arch Intern Med 2007;167:68-73
   PubMedGoogle Scholar
• Concato J, Shah N, Horwitz RI. Randomized, controlled trials, observational studies, and the hierarchy of research designs. N Engl J Med 2000;342:1887-92
   PubMed Web of Science ®Google Scholar
• Anglemyer A, Horvath HT, Bero L. Healthcare outcomes assessed with observational study designs compared with those assessed in randomized trials. Cochrane Database Syst Rev 2014;4:MR000034
   PubMed Web of Science ®Google Scholar
• European Medicines Agency (EMA). Xarelto^®, “Summary of Product Characteristics”. Updated 15 August 2013. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000944/WC500057108.pdf
   Google Scholar
• Patel MR, Mahaffey KW, Garg J, et al. ROCKET AF Investigators. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011;365:883-91
   PubMed Web of Science ®Google Scholar
• Salem JE, Sabouret P, Funck-Brentano C, Hulot JS. Pharmacology and mechanisms of action of new oral anticoagulants. Fundam Clin Pharmacol 2015;29:10-20
   PubMed Web of Science ®Google Scholar
• Kreutz R. Pharmacokinetics and pharmacodynamics of rivaroxaban - an oral, direct factor Xa inhibitor. Curr Clin Pharmacol 2014;9:75-83
   PubMedGoogle Scholar
• Kubitza D, Perzborn E, Berkowitz SD. The discovery of rivaroxaban: translating preclinical assessments into clinical practice. Front Pharmacol 2013;4:145
   PubMed Web of Science ®Google Scholar
• Agnelli G, Gallus A, Goldhaber SZ, et al. Treatment of proximal deep-vein thrombosis with the oral direct factor Xa inhibitor rivaroxaban (BAY 59-7939): the ODIXa-DVT (Oral Direct Factor Xa Inhibitor BAY 59-7939 in Patients With Acute Symptomatic Deep-Vein Thrombosis) study. Circulation 2007;116:180-7
   PubMed Web of Science ®Google Scholar
• Buller HR, Lensing AW, Prins MH, et al. A dose-ranging study evaluating once-daily oral administration of the factor Xa inhibitor rivaroxaban in the treatment of patients with acute symptomatic deep vein thrombosis: the Einstein-DVT Dose-Ranging Study. Blood 2008;112:2242-7
   PubMed Web of Science ®Google Scholar
• Kreutz R. A clinical and pharmacologic assessment of once-daily versus twice-daily dosing for rivaroxaban. J Thromb Thrombolysis 2014;38:137-49
   PubMed Web of Science ®Google Scholar
• Kubitza D, Roth A, Becka M, et al. Effect of hepatic impairment on the pharmacokinetics and pharmacodynamics of a single dose of rivaroxaban, an oral, direct Factor Xa inhibitor. Br J Clin Pharmacol 2013;76:89-98
   PubMed Web of Science ®Google Scholar
• Kubitza D, Becka M, Roth A, Mueck W. The influence of age and gender on the pharmacokinetics and pharmacodynamics of rivaroxaban – an oral, direct Factor Xa inhibitor. J Clin Pharmacol 2013;53:249-55
   PubMed Web of Science ®Google Scholar
• Hankey GJ, Patel MR, Stevens SR, et al. ROCKET AF Steering Committee Investigators. Rivaroxaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of ROCKET AF. Lancet Neurol 2012;11:315-22
   PubMed Web of Science ®Google Scholar
• Singer DE, Hellkamp AS, Piccini JP, et al. ROCKET AF Investigators. Impact of global geographic region on time in therapeutic range on warfarin anticoagulant therapy: data from the ROCKET AF clinical trial. J Am Heart Assoc 2013;2:e000067
   PubMed Web of Science ®Google Scholar
• Halperin JL, Bloomgarden Z, Hellkamp A, et al. Rivaroxaban compared with warfarin in patients with atrial fibrillation and diabetes: a subgroup analysis of the ROCKET AF trial. Circulation 2012;126(21 Meeting Abstracts):A15544
   Web of Science ®Google Scholar
• Fox KA, Piccini JP, Wojdyla D, et al. Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with non-valvular atrial fibrillation and moderate renal impairment. Eur Heart J 2011;32:2387-94
   PubMed Web of Science ®Google Scholar
• van Diepen S, Hellkamp AS, Patel MR, et al. Efficacy and safety of rivaroxaban in patients with heart failure and nonvalvular atrial fibrillation: insights from ROCKET AF. Circ Heart Fail 2013;6:740-7
   PubMed Web of Science ®Google Scholar
• Jones WS, Hellkamp AS, Halperin J, et al. Efficacy and safety of rivaroxaban compared with warfarin in patients with peripheral artery disease and non-valvular atrial fibrillation: insights from ROCKET AF. Eur Heart J 2014;35:242-9
   PubMed Web of Science ®Google Scholar
• Halperin JL, Hankey GJ, Wojdyla DM, et al. ROCKET AF Steering Committee and Investigators. Efficacy and safety of rivaroxaban compared with warfarin among elderly patients with nonvalvular atrial fibrillation in the Rivaroxaban Once Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF). Circulation 2014;130:138-46
   PubMed Web of Science ®Google Scholar
• Mahaffey KW, Stevens SR, White HD, et al. for the ROCKET AF Investigators. Ischaemic cardiac outcomes in patients with atrial fibrillation treated with vitamin K antagonism or factor Xa inhibition: results from the ROCKET AF trial. Eur Heart J 2014;35:233-41
   PubMed Web of Science ®Google Scholar
• Hori M, Matsumoto M, Tanahashi N, et al. on behalf of the J-ROCKET AF study investigators. Rivaroxaban vs. warfarin in Japanese patients with atrial fibrillation. Circ J 2012;76:2104-11
   PubMed Web of Science ®Google Scholar
• Liakoni E, Rätz Bravo AE, Terracciano L, et al. Symptomatic hepatocellular liver injury with hyperbilirubinemia in two patients treated with rivaroxaban. JAMA Intern Med 2014;174:1683-6
   PubMed Web of Science ®Google Scholar
• Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009;361:1139-51
   PubMed Web of Science ®Google Scholar
• Granger CB, Alexander JH, McMurray JJ, et al. Apixaban versus Warfarin in Patients with Atrial Fibrillation. N Engl J Med 2011;365:981-92
   PubMed Web of Science ®Google Scholar
• Giugliano RP, Ruff CT, Braunwald E, et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2013;369:2093-104
   PubMed Web of Science ®Google Scholar
• Kooiman J, van de Peppel WR, van der Meer FJ, Huisman MV. Incidence of chronic kidney disease in patients with atrial fibrillation and its relevance for prescribing new oral antithrombotic drugs. J Thromb Haemost 2011;9:1652-3
   PubMed Web of Science ®Google Scholar
• Barrios V, Escobar C, Calderón A, Zamorano JL. Prevalence of renal dysfunction according to the type of atrial fibrillation and anticoagulation treatment in patients who attended primary care in Spain. Future Cardiol 2014;10:215-20
   PubMedGoogle Scholar
• Register for New Oral Anticoagulants (NOAC). Available from: https://clinicaltrials.gov/ct2/show/NCT01588119
   Google Scholar
• Beyer-Westendorf J, Ebertz F, Gelbricht V, et al. Real life efficacy and safety of rivaroxaban for stroke prevention in atrial fibrillation: updated results of the prospective NOAC registry (NCT01588119). Presented at the European Society of Cardiology (ESC) congress, Amsterdam, The Netherlands, 31 Aug–4 Sept 2013. Eur Heart J 2013;34(Suppl):abstract 4870
   Google Scholar
• Ebertz F, Förster K, Gelbricht V, et al. Real life efficacy and safety of rivaroxaban for stroke prevention in atrial fibrillation – first results of the prospective NOAC Registry (NCT01588119) [abstract]. 55th American Society of Hematology (ASH) Annual Meeting and Exposition; New Orleans, LA; 7–10 December 2013. p. 213
   Google Scholar
• Beyer-Westendorf J, Förster K, Pannach S, et al. Rates, management, and outcome of rivaroxaban bleeding in daily care: results from the Dresden NOAC registry. Blood 2014;124:955-62
   PubMed Web of Science ®Google Scholar
• Fontaine GV, Mathews KD, Woller SC, et al. Major bleeding with dabigatran and rivaroxaban in patients with atrial fibrillation: a real-world setting. Clin Appl Thromb Hemost 2014;20:665-72
   PubMed Web of Science ®Google Scholar
• Pfeilschifter W, Luger S, Brunkhorst R, et al. The gap between trial data and clinical practice – an analysis of case reports on bleeding complications occurring under dabigatran and rivaroxaban anticoagulation. Cerebrovasc Dis 2013;36:115-19
   PubMed Web of Science ®Google Scholar
• Tamayo S, Frank Peacock W, Patel M, et al. Characterizing major bleeding in patients with nonvalvular atrial fibrillation: a pharmacovigilance study of 27 467 patients taking rivaroxaban. Clin Cardiol 2015;38:63-8
   PubMed Web of Science ®Google Scholar
• Abraham NS, Castillo DL. Novel anticoagulants: bleeding risk and management strategies. Curr Opin Gastroenterol 2013;29:676-83
   PubMed Web of Science ®Google Scholar
• Konturek P, Hess T. Gastrointestinal bleeding under treatment with new oral anticoagulants. MMW Fortschr Med 2014;156:50-2
   PubMedGoogle Scholar
• Beg S, Patel J, Bhuva M, et al. Mind over matter? Gastrointestinal bleeding due to the use of novel oral anticoagulants in stroke prevention. Presented at the British Society of Gastroenterology Annual General Meeting 16–19 June 2014. Gut 2014;63(Suppl 1):A58-9
   Google Scholar
• Laliberté F, Cloutier M, Nelson WW, et al. Real-world comparative effectiveness and safety of rivaroxaban and warfarin in patients with non-valvular AF. Presented at the American Heart Association 2013 Scientific Sessions and Resuscitation Science Symposium 26 November 2013. Circulation 2013;128(22 Suppl):A15875
   Google Scholar
• Laliberté F, Cloutier M, Nelson WW, et al. Real-world comparative effectiveness and safety of rivaroxaban and warfarin in nonvalvular atrial fibrillation patients. Curr Med Res Opin 2014;30:1317-25
   PubMed Web of Science ®Google Scholar
• Nelson WW, Song X, Coleman CI, et al. Medication persistence and discontinuation of rivaroxaban versus warfarin among patients with non-valvular atrial fibrillation. Curr Med Res Opin 2014;30:2461-9
   PubMed Web of Science ®Google Scholar
• Castellucci LA, Shaw J, van der Salm K, et al. Determinants of anticoagulation adherence using Morisky medication adherence scale [abstract COA36]. Presented at the 60th Meeting of the ISTH's Scientific and Standardization Committee (SSC), Milwaukee, USA, 23-26 June 2014. J Thromb Haemost 2014;12(Suppl 1):21
   Google Scholar
• Laliberté F, Nelson WW, Lefebvre P, et al. Impact of daily dosing frequency on adherence to chronic medications among nonvalvular atrial fibrillation patients. Adv Ther 2012;29:675-90
   PubMed Web of Science ®Google Scholar
• Larock AS, Mullier F, Sennesael AL, et al. Appropriateness of prescribing dabigatran etexilate and rivaroxaban in patients with nonvalvular atrial fibrillation: a prospective study. Ann Pharmacother 2014;48:1258-68
   PubMed Web of Science ®Google Scholar
• Ghanny S, Crowther M. Treatment with novel oral anticoagulants: indications, efficacy and risks. Curr Opin Hematol 2013;20:430-6
   PubMed Web of Science ®Google Scholar
• Laliberté F, Pilon D, Raut MK, et al. Hospital length of stay: is rivaroxaban associated with shorter inpatient stay compared to warfarin among patients with non-valvular atrial fibrillation? Curr Med Res Opin 2014;30:645-53
   PubMed Web of Science ®Google Scholar
• Ghijben P, Lancsar E, Zavarsek S. Preferences for oral anticoagulants in atrial fibrillation: a best-best discrete choice experiment. Pharmacoeconomics 2014;32:1115-27
   PubMed Web of Science ®Google Scholar
• Desai NR, Krumme AA, Schneeweiss S, et al. Patterns of initiation of oral anticoagulants in patients with atrial fibrillation - quality and cost implications. Am J Med 2014;127:1075-82.e1
   PubMed Web of Science ®Google Scholar
• Verhoef TI, Redekop WK, Hasrat F, et al. Cost effectiveness of new oral anticoagulants for stroke prevention in patients with atrial fibrillation in two different European healthcare settings. Am J Cardiovasc Drugs 2014;14:451-62
   PubMed Web of Science ®Google Scholar
• Morais J, Aguiar C, McLeod E, et al. Cost-effectiveness of rivaroxaban for stroke prevention in atrial fibrillation in the Portuguese setting. Rev Port Cardiol 2014;33:535-44
   PubMedGoogle Scholar
• Kourlaba G, Maniadakis N, Andrikopoulos G, Vardas P. Economic evaluation of rivaroxaban in stroke prevention for patients with atrial fibrillation in Greece. Cost Eff Resour Alloc 2014;12:5
   PubMed Web of Science ®Google Scholar
• Ynsaurriaga FA, Peinado RP, Ormaetxe Merodio JM. Atrial fibrillation and quality of life related to disease and treatment: focus on anticoagulation. Future Cardiol 2014;10:381-93
   PubMedGoogle Scholar
• Alegret JM, Viñolas X, Arias MA, et al. New oral anticoagulants vs vitamin K antagonists: benefits for health-related quality of life in patients with atrial fibrillation. Int J Med Sci 2014;11:680-4
   PubMed Web of Science ®Google Scholar
• Wyse DG, Waldo AL, DiMarco JP, et al. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med 2002;347:1825-33
   PubMed Web of Science ®Google Scholar
• Corley SD, Epstein AE, DiMarco JP, et al. Relationships between sinus rhythm, treatment, and survival in the Atrial Fibrillation Follow-Up Investigation of Rhythm Management (AFFIRM) Study. Circulation 2004;109:1509-13
   PubMed Web of Science ®Google Scholar
• Camm AJ, Lip GY, De Caterina R, et al. 2012 focused update of the. ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. Eur Heart J 2012;33:2719-47
   PubMed Web of Science ®Google Scholar
• Piccini JP, Stevens SR, Lokhnygina Y, et al. ROCKET AF Steering Committee & Investigators. Outcomes after cardioversion and atrial fibrillation ablation in patients treated with rivaroxaban and warfarin in the ROCKET AF trial. J Am Coll Cardiol 2013;61:1998-2006
   PubMed Web of Science ®Google Scholar
• Yadlapati A, Groh C, Passman R. Safety of short-term use of dabigatran or rivaroxaban for direct-current cardioversion in patients with atrial fibrillation and atrial flutter. Am J Cardiol 2014;113:1362-3
   PubMed Web of Science ®Google Scholar
• Cappato R, Ezekowitz MD, Klein AL, et al. on behalf of the X-VeRT Investigators. Rivaroxaban vs. vitamin K antagonists for cardioversion in atrial fibrillation. Eur Heart J 2014;35:3346-55
   PubMed Web of Science ®Google Scholar
• Haegeli LM, Calkins H. Catheter ablation of atrial fibrillation: an update. Eur Heart J 2014;35:2454-9
   PubMed Web of Science ®Google Scholar
• Verma A, Cairns JA, Mitchell LB, et al. CCS Atrial Fibrillation Guidelines Committee. 2014 focused update of the Canadian cardiovascular society guidelines for the management of atrial fibrillation. Can J Cardiol 2014;30:1114-30
   PubMed Web of Science ®Google Scholar
• Di Biase L, Burkhardt JD, Mohanty P, et al. Periprocedural stroke and management of major bleeding complications in patients undergoing catheter ablation of atrial fibrillation: the impact of periprocedural therapeutic international normalized ratio. Circulation 2010;121:2550-6
   PubMed Web of Science ®Google Scholar
• Santangeli P, Di Biase L, Horton R, et al. Ablation of atrial fibrillation under therapeutic warfarin reduces periprocedural complications: evidence from a meta-analysis. Circ Arrhythm Electrophysiol 2012;5:302-11
   PubMed Web of Science ®Google Scholar
• Eitel C, Koch J, Sommer P, et al. Novel oral anticoagulants in a real-world cohort of patients undergoing catheter ablation of atrial fibrillation. Europace 2013;15:1587-93
   PubMed Web of Science ®Google Scholar
• Lakkireddy D, Reddy YM, Di Biase L, et al. Feasibility and safety of uninterrupted rivaroxaban for periprocedural anticoagulation in patients undergoing radiofrequency ablation for atrial fibrillation: results from a multicenter prospective registry. J Am Coll Cardiol 2014;63:982-8
   PubMed Web of Science ®Google Scholar
• Bernard M, Brabham W, Netzler P, et al. Comparison of atrial fibrillation ablation bleeding and thrombotic complications with dabigatran, rivaroxaban and warfarin. Presented at the American College of Cardiology (ACC) Annual Meeting, San Francisco, USA, March 9–11 2013. J Am Coll Cardiol 2013;61:E276
   Web of Science ®Google Scholar
• Dillier R, Ammar S, Hessling G, et al. Safety of continuous periprocedural rivaroxaban for patients undergoing left atrial catheter ablation procedures. Circ Arrhythm Electrophysiol 2014;7:576-82
   PubMed Web of Science ®Google Scholar
• Musat DL, Garikipati N, Mittal S, et al. Novel oral anticoagulants (NOAC) vs warfarin peri-ablation for atrial fibrillation (AF): a meta-analysis of embolic and bleeding complications. Presented at American Heart Association (AHA) Scientific Sessions, Dallas, Texas, USA, 16–20 Nov 2013. Circulation 2013;128(22 Meeting Abstracts):A16938
   Web of Science ®Google Scholar
• Bockstall K, Gangireddy SR, The A, et al. The safety of performing catheter ablation of atrial fibrillation in patients taking rivaroxaban: a single-center [abstract P006-85]. Experience Presented at the Heart Rhythm Congress (HRC); 20–23 October 2013; Birmingham, UK
   Google Scholar
• Gadiyaram V, Boero I, Kawata H, et al. Rivaroxaban has similar Safety and efficacy as warfarin for peri-procedural anticoagulation for atrial fibrillation ablation [abstract PO01-165]. Presented at the Heart Rhythm Congress (HRC); 20–23 October 2013; Birmingham, UK
   Google Scholar
• Providência R, Marijon E, Albenque JP, et al. Rivaroxaban and dabigatran in patients undergoing catheter ablation of atrial fibrillation. Europace 2014;16:1137-44
   PubMed Web of Science ®Google Scholar
• Stepanyan G, Badhwar N, Lee RJ, et al. Safety of new oral anticoagulants for patients undergoing atrial fibrillation ablation. J Interv Card Electrophysiol 2014;40:33-8
   PubMed Web of Science ®Google Scholar
• Gomez-Outes A, Suarez-Gea ML, Lecumberri R, et al. Specific antidotes in development for reversal of novel anticoagulants: a review. Recent Pat Cardiovasc Drug Discov 2014;9:2-10
   PubMedGoogle Scholar
• Costin J, Ansell J, Laulicht B, et al. Reversal agents in development for the new oral anticoagulants. Postgrad Med 2014;126:19-24
   PubMed Web of Science ®Google Scholar
• Short NJ, Connors JM. New oral anticoagulants and the cancer patient. Oncologist 2014;19:82-93
   PubMed Web of Science ®Google Scholar